Lineage Cell Therapeutics (LCTX) EBITDA (2016 - 2025)
Historic EBITDA for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.8 million.
- Lineage Cell Therapeutics' EBITDA rose 140.62% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.2 million, marking a year-over-year decrease of 5477.78%. This contributed to the annual value of -$21.5 million for FY2024, which is 1316.06% up from last year.
- As of Q3 2025, Lineage Cell Therapeutics' EBITDA stood at -$3.8 million, which was up 140.62% from -$19.8 million recorded in Q2 2025.
- Lineage Cell Therapeutics' EBITDA's 5-year high stood at -$3.8 million during Q3 2025, with a 5-year trough of -$28.2 million in Q4 2021.
- Moreover, its 5-year median value for EBITDA was -$6.5 million (2025), whereas its average is -$7.8 million.
- Per our database at Business Quant, Lineage Cell Therapeutics' EBITDA plummeted by 38007.48% in 2021 and then soared by 7648.91% in 2022.
- Quarter analysis of 5 years shows Lineage Cell Therapeutics' EBITDA stood at -$28.2 million in 2021, then surged by 76.49% to -$6.6 million in 2022, then grew by 4.17% to -$6.4 million in 2023, then increased by 19.68% to -$5.1 million in 2024, then grew by 25.91% to -$3.8 million in 2025.
- Its EBITDA was -$3.8 million in Q3 2025, compared to -$19.8 million in Q2 2025 and -$6.5 million in Q1 2025.